Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Results of single head VDD-stimulation].

Herzschrittmachertherapie & Elektrophysiologie·2016

Same author

Current management of upper gastrointestinal bleeding.

Minerva chirurgica·2012

Same author

[Not Available].

Herzschrittmachertherapie & Elektrophysiologie·2009

Same author

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.

Current medical research and opinion·2007

Same author

Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.

Zeitschrift fur Kardiologie·2005

Same author

Nitric oxide-mediated endothelial dysfunction--is there need to treat?

Current vascular pharmacology·2004

Search research articles

Related Experiment Video

Updated: May 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Update on anti-coagulation in atrial fibrillation.

¹St. Vincenz Krankenhaus, Abteilung Kardiologie und Internistische Intensivmedizin, Auf dem Schafsberg, 65549 Limburg, Germany. j.kreuzer@st-vincenz.de

QJM : Monthly Journal of the Association of Physicians

|August 6, 2011

Summary

Atrial fibrillation (AF) affects millions, increasing stroke risk. Novel anticoagulants like dabigatran etexilate offer improved efficacy and safety over warfarin for stroke prevention in AF patients.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: May 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

Cardiology
Pharmacology
Public Health

Background:

Atrial fibrillation (AF) is a prevalent arrhythmia causing significant morbidity and mortality.
AF prevalence increases with age and is linked to comorbidities like hypertension and diabetes.
Anticoagulation is crucial for stroke prevention in AF patients, with warfarin being a traditional but under-used option.

Purpose of the Study:

To review current pharmacotherapy for atrial fibrillation (AF).
To discuss the role of anticoagulation in stroke prevention for AF patients.
To evaluate novel anticoagulants, specifically dabigatran etexilate, as alternatives to warfarin.

Main Methods:

Review of current literature on AF pharmacotherapy and anticoagulation.
Analysis of clinical trial data comparing warfarin with novel anticoagulants for stroke prevention in AF.
Examination of the efficacy, safety, and practical considerations of different treatment options.

Main Results:

Warfarin, while effective, has limitations including a narrow therapeutic window and monitoring requirements.
Novel oral anticoagulants, such as dabigatran etexilate, demonstrate improved efficacy and safety profiles compared to warfarin.
Dabigatran etexilate has received regulatory approval and shows potential to replace warfarin in AF stroke prevention.

Conclusions:

New therapeutic options, including novel anticoagulants and improved anti-arrhythmic agents, are enhancing AF patient care.
Dabigatran etexilate represents a significant advancement in stroke prevention for AF patients.
The landscape of AF treatment is evolving, offering better management strategies and outcomes.